GSK Earnings Today: Arexvy Rollout and Zantac Settlement in Focus
As seen on the 24/7 Wall St. homepage on July 28, 2026.
GSK reports before the bell today with Arexvy RSV vaccine rollout and Zantac litigation resolution both in focus for investors watching the pharma giant's commercial momentum.
Continue ReadingShow less
GlaxoSmithKline is reporting before the market opens on July 28, 2026, giving investors their first detailed look at how the company's commercial momentum is holding up. Two storylines are drawing particular attention: the ongoing rollout of Arexvy, GSK's RSV vaccine, and the resolution of Zantac litigation that has long weighed on the company's legal outlook.
The Arexvy rollout represents one of GSK's most closely watched growth drivers, as the RSV vaccine market has become a key battleground for major pharmaceutical players. How management characterizes demand, pricing power, and competitive positioning in that space will likely set the tone for how the stock trades after the report.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
The Zantac litigation resolution removes a cloud that has shadowed GSK for years, and investors will be listening for any guidance on remaining financial exposure or one-time charges tied to that settlement. Together, these two developments give today's report unusual weight even by the standards of a large-cap pharma earnings day.
Sources
Mentioned: GSK